Regarding this strategy, we have demonstrated that dual targeting of PD‐L1 and HLA‐G, in combination with chemotherapy, potentiates the cytotoxicity of T lymphocytes against NSCLC.[10]. The gene discussed is HLA-G; the disease is non-small cell lung carcinoma.